These aggregates further increase during exacerbations, suggesting a plausible biological mechanism to explain the increased cardiovascular risk seen in ECOPD. Taken together, these studies confirm the view that ECOPD episodes requiring hospitalisation must be considered very severe events in the natural course of the disease because they are associated with such important outcomes as increased risk of mortality, reduced health status, impaired lung function, muscle weakness, and cardiopulmonary complications. 4 The studies also suggest that the increased risk of death is often due to acute cardiovascular involvement, and they highlight the limitations of the current definition of ECOPD and the need to move towards a more comprehensive definition, diagnostic approach and treatment.
RISK OF DEATH AND EXACERBATIONS OF COPD
Several previous studies have clearly established that episodes of ECOPD are a major driver of mortality in this disease, especially during and immediately after the acute event. (The long-term effects are discussed in next paragraph.) For instance, in a cohort of 1016 patients hospitalised because of ECOPD with hypercarbia (PaCO 2 $50 mm Hg), Connors et al 5 reported that mortality was 11% in hospital, and 20%, 33%, 43% and 49%, respectively, at 60 days, 180 days, 1 year, and 2 years after discharge. More recently, Chang et al 6 reported that mortality during the first 30 days after hospitalisation varied between 2% and 21% according to the CURB65 score. CURB65 is a composite index based on confusion, blood urea, respiratory rate, blood pressure and age that was developed to predict mortality risk in community-acquired pneumonia. 6 Together these studies demonstrate that mortality during and immediately after hospitalisation for ECOPD is remarkably high.
Episodes of ECOPD also affect longterm mortality. This is best illustrated by the study of Soler-Cataluña et al, 7 who followed a cohort of 304 patients with COPD for 5 years and found that mortality increased in direct proportion to the frequency of ECOPD; that is, patients with frequent episodes (three or more) had the greatest mortality risk (HR 4.13; 95% CI 1.80 to 9.41). In agreement with Connors et al, 5 Soler-Cataluña et al also found that arterial hypercarbia was an independent marker of poor prognosis (HR 1.07; 95% CI 1.02 to 1.12). 
CARDIOVASCULAR DISEASE AND EXACERBATIONS OF COPD
ECOPD. After analysing data from 25 857 patients with COPD who were entered in the Health Improvement Network database over a 2-year period, Donaldson et al reported that the risk of myocardial infarction 1e5 days after an ECOPD episode increased 2.3-fold (95% CI 1.1 to 4.7; p¼0.03), and that the risk of stroke 1e49 days after ECOPD increased 1.3-fold (95% CI 1.0 to 1.6; p¼0.05). 9 Furthermore, a 2009 retrospective postmortem study of patients who died within 24 h of hospitalisation because of ECOPD showed that cardiac failure and thromboembolism were the principal causes of death.
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The mechanisms linking COPD and CVD are unclear, but the presence of lowgrade chronic systemic inflammation is likely to be an important one. Systemic inflammation increases during ECOPD, 14 15 providing a potential mechanism to explain the increased risk of vascular events associated with ECOPD. 9 The three studies published in this issue provide new information that can contribute to a better understanding of the relationship between ECOPD, inflammation and cardiovascular events. The first two studies 1 2 found that the plasma levels of the cardiac biomarkers NTproBNP and troponin T were abnormal in a significant number of patients hospitalised because of ECOPD, and that both markers predicted mortality 1 2 even after adjusting for other predictors of mortality such as PaCO 2 or CURB65 score. 1 The third study found that, compared with healthy controls, patients with COPD had increased circulating plateletemonocyte aggregates, which were further increased during ECOPD. 3 Together these findings suggest that cardiovascular involvement in ECOPD may be an important determinant of prognosis and death, opening new avenues for research of novel diagnostic and therapeutic strategies. Unfortunately, the current definition of ECOPD is still very much descriptive and clinical. Episodes of ECOPD are defined as acute events characterised by a change in the patient's baseline dyspnoea, cough, and/or sputum that is beyond normal dayto-day variations; in a patient with underlying COPD, these events may warrant a change in medication. 16e18 However, while this definition may be useful in epidemiologic studies, 19 it is often of limited use in the clinical setting. It is suggested that more than half of ECOPD episodes are caused by viral and bacterial infections or pollutants. These exacerbations are most likely associated with the three cardinal respiratory symptoms, increased sputum, purulent sputum and dyspnoea. In these cases, dyspnoea most likely worsens because of increased inflammation of the airways and the lung due to the infection or pollutant. However, patients with COPD often have several concomitant disorders. Therefore acute inflammation of the airways and the lung may not only worsen dyspnoea by affecting the respiratory system, but may also have systemic effects because of acute systemic inflammation and thus cause dyspnoea by affecting the cardiovascular or metabolic system. Moreover, other conditions, such as pulmonary embolism, acute cardiac failure, pneumonia, pneumothorax and anaemia, can mimic ECOPD by precipitating respiratory symptoms, particularly dyspnoea. Considering this complexity of causes, we suggest that the term 'exacerbations of COPD' be changed to 'exacerbations of respiratory symptoms in patients with COPD'. For the same reason, there is great interest in identifying biomarkers that can facilitate a more precise diagnosis of ECOPD and its aetiology. The three studies published in this issue suggest that serum biomarkers such as troponin T and NT-BNP may not only identify patients at increased risk of death but may also help to determine the relative role of extra-respiratory events, such as acute heart failure or thromboembolism, and that of other causes of acute dyspnoea in patients with COPD.
LIMITATIONS OF THE CURRENT DEFINITION OF EXACERBATION OF COPD

NEED FOR A MORE COMPREHENSIVE DIAGNOSTIC AND THERAPEUTIC APPROACH
These three articles 1e3 extensively discuss the mechanisms underlying the increased levels of cardiac biomarkers and platelet activation during ECOPD, as well as their clinical significance. The increase in troponin T and NT-BNP may be due to several different causes, including systemic inflammation, respiratory failure, coronary artery disease, left ventricular dysfunction, right ventricular pressure overload due to pulmonary hypertension, or pulmonary thromboembolism. However, platelet activation might not only be due to systemic inflammation but also to other concomitant chronic conditions such as rheumatoid arthritis or diabetes, or acute conditions such as hypoxaemia, tachycardia and hyperglycemia, all predictors of poor outcome in patients with ECOPD. 4 8 Guidelines provide clear evidence-based recommendations on how to diagnose and treat respiratory abnormalities during ECOPD episodes, but provide little direction on how to deal with concomitant abnormalities in patients with COPD. Considering the high risk of cardiovascular complications and death from ECOPD, we agree with the authors of the three studies discussed here that, while awaiting the generation of the necessary scientific evidence, patients hospitalised because of ECOPD should be carefully examined for the relevant biomarkers and for any concomitant abnormality that may call for specific therapy. This in line with the recent editorial of 
